Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRN-010
- Development stage
- Preclinical
- Lead developer
- Turn Biotechnologies
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Ex Vivo
01
Overview
TRN-010 is an mRNA-based therapeutic candidate developed by Turn Biotechnologies, currently in the preclinical stage for the treatment of immune system diseases and the enhancement of oncology treatments such as CAR-T cell therapy. The drug utilizes Turn's proprietary Epigenetic Reprogramming of Aging (ERA) technology, which involves the delivery of mRNA encoding specific transcription factors to rejuvenate aged or exhausted immune cells. Delivered via the eTurna lipid nanoparticle (LNP) system, TRN-010 has demonstrated the ability to increase T-cell proliferation and cytotoxic activity against cancer cells by up to fivefold in preclinical models, potentially offering improved potency and patient tolerability compared to existing therapies.
Beyond the preview
Go deeper on TRN-010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRN-010.